The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive, percutaneous coronary intervention (PCI) procedures can perform as well or better than the gold-standard of coronary artery bypass graft surgery (CABG).


The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive, percutaneous coronary interventions (PCI) procedures can perform as well or better than the gold-standard of coronary artery bypass graft surgery (CABG). Abbott Vascular is now pitting its Xience V stent against CABG in a new trial.

October 7, 2011 — There is good news for cancer patients whose medical treatments put them at risk for future cardiac problems: using strain echocardiography can help physicians detect early signs of cardiac toxicity. To get this information out, the American Society of Echocardiography (ASE) is preparing a guideline document outlining the best way to evaluate cancer patients. ASE has also funded a research study to enhance identification of patients who are at risk.

October 7, 2011 – ValveXchange Inc., has performed successful first-in-man (FIM) surgeries demonstrating the practicality and advantages of its novel Vitality two-part heart valve system. Two renowned United States cardiac surgeons, Lars Svensson, M.D., Ph.D., of The Cleveland Clinic and W. Randolph Chitwood, M.D. of The East Carolina Heart Institute, performed the surgeries; they were working with Adrian Ebner, M.D. at his facilities in Asuncion, Paraguay.

October 7, 2011 — Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and, as a result of their deteriorating health, cannot enjoy a normal lifestyle.

October 7, 2011 — U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, M.D., released a blueprint containing immediate steps to drive biomedical innovation, while improving the health of Americans.

October 7, 2011 — Boston Scientific Corp. has started patient enrollment in the Omega clinical trial, designed to evaluate the company's Omega platinum chromium bare-metal coronary stent system. The trial will test the safety and effectiveness of OMEGA in treating patients with a single coronary artery lesion.

Digging through boxes, waiting for couriers, finding smashed VHS tapes in the mail, jockeying back and forth between multiple modalities. Like at other hospitals across the country, the manual, tape- and film-based workflow in the pediatric cardiology department at Mercy Children’s Hospital in Toledo, Ohio, had stagnated. The workflow had quadrupled in the time it took the cardiologists to read echocardiograms for the hospital and four outreach centers, resulting in a report turnaround time that could be as long as five to seven days.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now